Head-to-head · WeighScore
AM Rx vs Obu Health
The verdict
Obu Health takes it — 59.7/100 to 49.6/100.
Obu Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Obu Health is a Las Vegas-based multi-product telehealth platform offering compounded semaglutide from $190/month and compounded tirzepatide from $239/month, plus NAD+ and sermorelin add-ons.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | AM Rx | Obu Health |
|---|---|---|
| WeighScore | 49.6/100 | 59.7/100 |
| Grade | C | C |
| Scorecard rank | #491 | #336 |
| Semaglutide | $151/mo (quarterly plan, plus a separate fee, compounded) | $190/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | Not disclosed | $239/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #491 · C
Strengths
- Insurance coordination for brand-name GLP-1s — as low as $25/mo
- All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
- HSA and FSA accepted
- Video visits available with providers averaging 10+ years' experience
- Compounded semaglutide from $151/mo on the quarterly plan
Where it loses points
- Active FTC/DOJ lawsuit over deceptive billing and subscription practices
- Novo Nordisk false-advertising lawsuit (Aug 2025)
- Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
- Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #336 · C
Strengths
- LegitScript-certified with publicly displayed ID (44206977)
- Two named 503A compounding-pharmacy partners (Manifest Pharmacy SC + RX Compounding Store FL) — transparency above category baseline
- Lower advertised semaglutide starting price ($190) than most multi-product peer platforms
- Multi-product offering (GLP-1s + NAD+ + sermorelin + generic ED + birth control) for single-platform users
- 24-hour US board-certified physician response window
Where it loses points
- Per-dose pricing tiers not transparently published on product pages — only 'starting from' prices visible
- No explicit state-coverage list disclosed; FAQ confirms restrictions exist 'based on state' without enumeration
- Medical director not named publicly
- No published consultation fee disclosure — unclear whether physician visit is included in medication price
- All sales final per FAQ ('Federal and State law do not allow medication returns')
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.